NDUFA5
ENSG00000128609
Target class
Enzyme
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFA5
- Gene name
- NADH:ubiquinone oxidoreductase subunit A5
- Gene symbol
- NDUFA5
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 (Complex I subunit B13) (Complex I-13kD-B) (CI-13kD-B) (NADH-ubiquinone oxidoreductase 13 kDa-B subunit)
- B13
- NUFM
- CI-13KD-B
- UQOR13
- CI-13kB
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 51.57
- Tissue specificity (Gini)
- 0.225
- Tissue specificity (tau)
- 0.565
- KEGG gene identifiers
- hsa:4698
- Protein interaction confidence
- 0.912773
- Protein interaction partners
- 128
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9013408
- End position
- 123557904
- Start position
- 123536997
- Chromosome
- 7
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.564607
- Expression inequality (Gini)
- 0.225
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 51.57
- Brain - Anterior cingulate cortex (BA24)
- 41.55
- Brain - Cerebellar Hemisphere
- 41.18
- Muscle - Skeletal
- 37.23
- Brain - Cortex
- 33.99
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)51.57
- Brain - Anterior cingulate cortex (BA24)41.55
- Brain - Cerebellar Hemisphere41.18
- Muscle - Skeletal37.23
- Brain - Cortex33.99
- Thyroid33.91
- Brain - Hypothalamus33.89
- Brain - Nucleus accumbens (basal ganglia)33.82
- Esophagus - Muscularis31.51
- Brain - Amygdala31.39
- Heart - Atrial Appendage31.25
- Brain - Cerebellum30.79
- Esophagus - Gastroesophageal Junction29.89
- Heart - Left Ventricle29.47
- Adrenal Gland28.64
- Brain - Caudate (basal ganglia)28.43
- Colon - Sigmoid28.1
- Pituitary27.74
- Kidney - Medulla26.95
- Brain - Hippocampus24.94
- Brain - Substantia nigra24.51
- Artery - Tibial24.4
- Brain - Putamen (basal ganglia)23.13
- Uterus22.93
- Brain - Spinal cord (cervical c-1)22.81
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor